The ruling is final at the trial court level; ANI may appeal to the Delaware Supreme Court. Monitor for any appeal notice or settlement discussions. CG Oncology's CG0070 commercialization path is now free of this royalty overhang, which may be positive for CG Oncology's valuation.
Price Chart
Executive Summary
The Delaware Superior Court denied ANI Pharmaceuticals' motion for a new trial and judgment as a matter of law, upholding a jury verdict that the invalidation of a perpetual royalty provision in ANI's 2010 agreement with CG Oncology was not materially adverse to ANI. The ruling confirms that CG Oncology owes no further royalties on CG0070 sales post-patent expiration, and the remainder of the contract survives via severability, barring ANI's unjust enrichment claim.
Court Ruling Details
Key Facts
- Jury found that invalidation of §3.3 royalty provision did not materially adversely affect ANI under the contract's severability clause (§7.7).
- Court denied ANI's motion for new trial and judgment as a matter of law, upholding the verdict.
- ANI had sought perpetual royalties on net sales of CG Oncology's bladder cancer drug CG0070; the court ruled the perpetual royalty unenforceable under Brulotte v. Thys Co.
- The contract survives via severability; ANI's alternative unjust enrichment claim is precluded.
- CG Oncology completed its IPO in January 2024; ANI initiated the lawsuit in March 2024.
Financial Impact
ANI loses all future royalty revenue from CG0070 sales (5% running royalty on net sales). The jury found no material adverse effect, so no damages or restitution were awarded.
Risk Factors
- ANI may appeal the ruling to the Delaware Supreme Court, potentially reversing the verdict.
- Loss of perpetual royalty stream reduces ANI's long-term revenue potential from the CG0070 asset.
- No damages or settlement were awarded; ANI receives no compensation for the severed royalty provision.
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-a3d1f282d5-ANIP |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Insider Cluster | $72.56 | awaiting T+60 | — | $71.17 (+1.92%) |
Sep 23, 2026 4w ago | Press Release | $74.43 | awaiting T+60 | — | $71.17 (−4.38%) |
Sep 16, 2026 5w ago | Insider Cluster | $75.39 | awaiting T+60 | — | $71.17 (−5.60%) |
Sep 14, 2026 6w ago | Insider Cluster | $72.11 | awaiting T+60 | — | $71.17 (−1.30%) |
Sep 1, 2026 7w ago | Insider Cluster | $73.06 | awaiting T+60 | — | $71.17 (−2.59%) |
Aug 24, 2026 9w ago | 8-K | $74.17 | awaiting T+60 | — | $71.17 (−4.04%) |
Aug 13, 2026 10w ago | Insider Cluster | $76.54 | awaiting T+60 | — | $71.17 (−7.02%) |
Aug 7, 2026 11w ago | 8-K | $78.25 | awaiting T+60 | — | $71.17 (−9.05%) |
Jul 16, 2026 14w ago | Court Ruling | $79.20 $73.59 | ▲ +7.08% | ▲ +11.77% | $71.17 (+10.14%) |
Jul 13, 2026 15w ago | Press Release | $81.08 $71.52 | ▼ −11.79% | ▼ −15.78% | $71.17 (−12.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers